Mr. Halak joined Domain in 2001 and became a Partner in 2006. He currently serves on the Board of Alimera Sciences, GI Dynamics, Immune Control, Optherion, Pharmena, Tobira Therapeutics and Vanda Pharmaceuticals. He was previously on the board of Esprit Pharma until the company was acquired by Allergan. From 2000 to 2001, Mr. Halak was an Associate with Advanced Technology Ventures where he participated in the firms investments in Plexxikon, Percardia and Emphasys. From 1993 to 1995, he was a Consultant at the Wilkerson Group where he developed strategy for pharmaceutical and medical device companies. Mr. Halak is currently a member of the Investment Advisory Council for Ben Franklin Technology Partners and BioAdvance, both seed-stage investment groups in Philadelphia. He also serves as an advisor to Elm Street Ventures.